Cullinan Therapeutics Inc logo

Cullinan Therapeutics Inc

CGEM
Healthcare|Biotechnology|USA
$18.13
-0.24 (-1.31%)
Tangible Book
$5.96
Earnings Power
$7.63

About

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Stock Price

+131.3%(1Y)

Pipeline Summary

10 total trials
10
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Active: 4Recruiting: 4Terminated: 2

Active Trials (8)

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
NCT05879744NHL
Phase 1Active
Enrollment: 90 participants
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05117476Advanced Solid Tumor
Phase 1Active
Enrollment: 440 participants
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141Multiple Myeloma
Phase 1Active
Enrollment: 30 participants
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099Sjögren
Phase 1Recruiting
Enrollment: 36 participants
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer
Phase 1Phase 2Active
Enrollment: 284 participants
View all 8 active trials →

BioScore

3.4/10
High Risk

Ownership

Recent Insider Trades

Michaelson JenniferSELL
2026-07-068,000 shares @ $17.82
Michaelson JenniferSELL
2026-05-058,000 shares @ $14.62
Michaelson JenniferSELL
2026-03-058,000 shares @ $15.68
Michaelson JenniferSELL
2026-02-251,780 shares @ $14.14
Jones Jeffrey AlanSELL
2026-02-244,582 shares @ $14.47
Data last updated: Jul 13, 2026, 12:47 PM